Celltrion Healthcare presented new data on their Rituximab biosimilar Truxima® (CT-P10) at the International Conference on Malignant Lymphoma (ICML) in Switzerland and the European League Against Rheumatism (EULAR) Congress 2017 in Spain. According to the presentation, data from a randomized, double-blind, controlled phase III study in 140 patients indicate that Truxima® is comparable to reference rituximab in efficacy and safety for both oncology and autoimmune indications.
The post New Data Supports Efficacy and Safety of Celltrion’s Rituximab Biosimilar appeared first on Big Molecule Watch.